SCHEMBL6077867

SCHEMBL6077867

CCC(CCN(C)C(=O)OC(C)(C)C)SC(=O)c1ccccc1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GBA1 P04062 1/20 0.39
GPR88 Q9GZN0 1/20 0.38
CYP1A2 P05177 1/20 0.37
CYP2D6 P10635 1/20 0.37
CYP2C19 P33261 1/20 0.37
HTR2C P28335 2/20 0.36
SLC6A4 P31645 2/20 0.36
KMT2A Q03164 1/20 0.36
PDK2 Q15119 1/20 0.36
AAK1 Q2M2I8 1/20 0.36
JAK3 P52333 1/20 0.35
BTK Q06187 1/20 0.35
HDAC3 O15379 1/20 0.34
HDAC1 Q13547 1/20 0.34
HDAC2 Q92769 1/20 0.34
NCOR2 Q9Y618 1/20 0.34
L3MBTL1 Q9Y468 1/20 0.34
CTSK P43235 3/20 0.33
PRSS1 P07477 1/20 0.33
CTSG P08311 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6332355 0.93 GPR88 (0.42) GBA1GPR88CYP1A2CYP2D6CYP2C19
SCHEMBL6077869 0.75 JAK3 (0.41) CYP2D6AAK1JAK3BTKL3MBTL1
SCHEMBL23506470 0.74 SLC6A2 (0.42) KMT2APRSS1CTSGCTRB1CMA1
SCHEMBL6493570 0.73 GPR88 (0.41) GBA1GPR88HTR2CSLC6A4KMT2A
SCHEMBL6050417 0.73 RIPK1 (0.51) GBA1GPR88HTR2CSLC6A4KMT2A
SCHEMBL525671 0.73 RIPK1 (0.51) GBA1GPR88HTR2CSLC6A4KMT2A
SCHEMBL6050532 0.73 RIPK1 (0.51) GBA1GPR88HTR2CSLC6A4KMT2A
SCHEMBL21848475 0.72 KMT2A (0.58) GBA1CYP1A2CYP2D6CYP2C19HTR2C
SCHEMBL21853987 0.72 GPR88 (0.43) GBA1GPR88HTR2CSLC6A4KMT2A
SCHEMBL23699370 0.72 GPR88 (0.43) GBA1GPR88CYP2C19HTR2CSLC6A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7119109-B2 Heteroarylheteroalkylamine derivatives and their use as inhibitors of nitric oxide synthase ASTRAZENECA AB (SE) 2006-10-10 US disclosed
US-20040220234-A1 Heteroarylheteroalkylamine derivatives and their use as inhibitors of nitric oxide synthase ASTRAZENECA AB (SE) 2004-11-04 US disclosed
EP-1421067-A1 HETEROARYLHETEROALKYLAMINE DERIVATIVES AND THEIR USE AS INHIBITORS OF NITRIC OXIDE SYNTHASE AstraZeneca AB (SE) 2004-05-26 EP disclosed
WO-2003011831-A1 HETEROARYLHETEROALKYLAMINE DERIVATIVES AND THEIR USE AS INHIBITORS OF NITRIC OXIDE SYNTHASE ASTRAZENECA AB (SE) 2003-02-13 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040220234-A1 Heteroarylheteroalkylamine derivatives and their use as inhibitors of nitric oxide synthase NOS3, NOS2, NOS1 GBA1 1699/4885GPR88 1395/4885CYP1A2 4/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.